Treatment of Atopic Dermatitis and Psoriasis Vulgaris With Bupropion-SR: A Pilot Study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine whether the antidepressant bupropion may be useful in treating atopic dermatitis and psoriasis in nondepressed patients. METHOD: Ten nondepressed subjects with atopic dermatitis and 10 with psoriasis completed a single-track, open-label treatment protocol with bupropion-SR in doses of 150 mg/day and 300 mg/day, administered sequentially for 3 weeks each, followed by a 3-week wash-out. Treatment response was assessed at the end of each 3-week period. RESULTS: Six of the 10 subjects with atopic dermatitis showed a reduction in affected body surface area by the end of 6 weeks of bupropion treatment, with affected area increasing toward the prestudy baseline in all responders following bupropion discontinuation-a highly significant treatment effect (p =.0003). Of the 10 subjects having psoriasis, improvement over baseline after 6 weeks of treatment was seen in eight subjects, with coverage increasing toward the prestudy baseline in the responders following bupropion discontinuation (p =.001). Average reduction in affected area in the responders at week 6 of treatment was approximately 50% in both groups. CONCLUSIONS: The generally good tolerability and relative safety of bupropion-SR makes a trial of this agent worthwhile in patients with atopic dermatitis or psoriasis who have failed treatment with more conventional medications. Normalization by bupropion of potentially causative neuroendocrine, immunologic, or catecholaminergic abnormalities in both of these dermatologic disorders is a possible mechanism of action for the observed salutary effects of this drug on our subjects' skin disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kubera, M., Lin, A.-H., Kenis, G., Bosmans, E., van Bockstaele, D., & Maes, M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00012 · Cited by 343
Cited by
Steinhoff, M., Suárez, A., Feramisco, J., & Koo, J. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1188 · Cited by 263
Martino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111
“In a study on non-depressed patients with psoriasis, bupropion proved to be effective in reducing skin lesions, as it showed an effectiveness, albeit less incisive, in patients with atopic dermatitis [378]; also MAOIs have shown an efficacy in these conditions [379].”
BackgroundKast, R. E. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(03)00093-8 · Cited by 62
Empirically supported use of psychiatric medications in adolescents and adults with IBD
Thorkelson, G., Bielefeldt, K., & Szigethy, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000734 · Cited by 39
Metadata
- Authors
- Modell, J. G., Boyce, S., Taylor, E., & Katholi, C.
- Venue
- Psychosomatic Medicine
- Published
- 2002-09
- Volume
- 64
- Issue
- 5
- Pages
- 835-840
- ISSN
- 0033-3174 (ISSN-L)
- OpenAlex
- W2066261542
- Cited by
- 53
- References
- 1
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Atopic Dermatitis and Psoriasis Vulgaris With Bupropion-SR: A Pilot Study. https://app.cochat.ai/papers/10.1097/00006842-200209000-00017
- The paper
- Modell, J. G., Boyce, S., Taylor, E., & Katholi, C. (2002). Treatment of Atopic Dermatitis and Psoriasis Vulgaris With Bupropion-SR: A Pilot Study. Psychosomatic Medicine. https://doi.org/10.1097/00006842-200209000-00017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.